TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1969068
Drug: Conventional perioperative
Normalized name: ENSURE SURGERY PERIOPERATIVE KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional perioperative antibiotic prophylaxis (controls)
Study: 21543951
Drug: Dual-focus schema
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-focus schema therapy
Study: 25799306
Drug: Individual drug
Normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Individual drug counseling
Study: 19483514
Drug: 11-valent pneumococcal
Normalized name: Streptococcus pneumoniae serotype 10A capsular antigen diphtheria CRM197 protein conjugate vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-valent pneumococcal conjugate vaccine (11PCV)
Study: 10361108
Drug: TAD-HAM (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAD-HAM (high-dose cytarabine with mitoxantrone)
Study: 10361108
Drug: TAD (standard-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAD (standard-dose cytarabine with daunorubicin and 6-thioguanine)
Study: 2155476
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drugs (NSAIDs) including acetylsalicylic acid, carprofen, diclofenac, indomethacin, naproxen, proquazone, timegadine, tolfenamic acid, paracetamol
Study: 31719078
Drug: Nasogastric (NG)
Normalized name: NG
DrugBank: Nitroglycerin (DB00727)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasogastric (NG) route - 8 infusions over 4 days, then again for 4 days in week 4 (total of 240 g of stool)
Study: 31719078
Drug: Colonoscopic infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Colonoscopic infusion followed by seven weekly enemas (total of 360 g of stool)
Study: 26209856
Drug: Single intraoperative
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intraoperative dose of dexamethasone
Study: 22132755
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment at 4 acupuncture points, ST23 and ST27, bilaterally, 3 times per week for four weeks.
Study: 20084933
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment
Study: 17087245
Drug: Clexane, 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clexane, 40 mg, administered 12 hours before and within 7-18 days after surgery
Study: 15021224
Drug: High-risk OH
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk OH and Primary Open Angle Glaucoma (POAG) treatment
Study: 9286520
Drug: Chewing gum
Normalized name: Chewing Gum
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chewing gum containing 0.25 mg F as NaF for 5, 10, 15, 20, 30, or 45 minutes
Study: 12959292
Drug: Modified metered‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified metered‐dose actuator device (MA)
Study: 12959292
Drug: Standard metered‐dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard metered‐dose inhaler (MDI)
Study: 31096498
Drug: Oral carbohydrate
Normalized name: omega-3 carboxylic acids Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral carbohydrate solution 710 mL the night before and 355 mL 2 hours prior to operation
Study: 23032410
Drug: Monotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy with ritonavir-boosted lopinavir (LPV/r)
Study: 23032410
Drug: Continued therapy
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continued therapy
Study: 16957558
Drug: Methionine 100
Normalized name: methionine 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine 100 mg/kg (study 1)
Study: 16957558
Drug: Methionine 200
Normalized name: methionine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methionine 200 mg/kg (study 2)
Study: 15354036
Drug: Glucose infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose infusion (20% in saline; carbohydrate (CHO) at a rate of 1 g x min(‐1))
Study: 7978956
Drug: Gonadotropin‐releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gonadotropin‐releasing hormone agonist (GnRHa) in depot formulation (Zoladex) with transdermal 17‐beta‐estradiol and oral progestin
Study: 31702802
Drug: Bimodal release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bimodal release ondansetron (6 mg immediate release and 18 mg 24-hour release, total 24 mg)
Study: 28229892
Drug: Opicinumab (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicinumab (100 mg/kg intravenously once every 4 weeks for six doses)
Study: 28229892
Drug: Placebo (intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (intravenously once every 4 weeks for six doses)
Study: 23116775
Drug: Iron supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation (ferrous sulfate, 10 mg of elemental iron per day)
Study: 21349218
Drug: Praziquantel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (40 mg/kg) + Mebendazole (500 mg)
Study: 21349218
Drug: Praziquantel (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Praziquantel (40 mg/kg) alone
Study: 19346844
Drug: Intravenous beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous beta-blocker (landiolol hydrochloride, mean dose of 0.032 mg/kg per minute)
Study: 19346844
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of intravenous beta-blocker and sublingual NTG (0.3 mg)
Study: 11304056
Drug: Chloroquine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (25 mg/kg over 48 hours)
Study: 11304056
Drug: Halofantrine (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Halofantrine (8 mg/kg, 3 doses)
Study: 1505554
Drug: Reference, hospital-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reference, hospital-based treatment (H) group
Study: 28772281
Drug: Linsitinib 150
Normalized name: Linsitinib
DrugBank: Linsitinib (DB06075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Linsitinib 150 mg BID plus erlotinib 150 mg QD
Study: 28772281
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus erlotinib 150 mg QD
Study: 26964164
Drug: Acupoint application
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupoint application therapy with bushentongyu plaster and tamsulosin hydrochloride (0.2 mg every night for 100 days)
Study: 26964164
Drug: Tamsulosin hydrochloride
Normalized name: Tamsulosin Hydrochloride
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamsulosin hydrochloride (0.2 mg every night for 100 days)
Study: 23767986
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg daily oral rasagiline (monotherapy)
Study: 23767986
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg daily oral rasagiline (adjunct therapy with levodopa)
Study: 23767986
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg daily oral rasagiline (adjunct therapy)
Study: 21285525
Drug: Self-stretching and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-stretching and soft tissue TrP manual therapy (Str-ST)
Study: 3913728
Drug: Warfarin and
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin and Control
Study: 3304625
Drug: Intensive course
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive course of chemotherapy consisting of vincristine, procarbazine and methotrexate, followed by citrovorum factor rescue
Study: 29022212
Drug: Saroglitazar magnesium
Normalized name: Magnesium
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saroglitazar magnesium 4-mg tablet under fed conditions (high-calorie and high-fat breakfast)
Study: 29022212
Drug: Saroglitazar magnesium
Normalized name: Magnesium
DrugBank: Saroglitazar (DB13115)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saroglitazar magnesium 4-mg tablet under fasting conditions
Study: 23672318
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia (0.25 mg/kg bupivacaine 0.5%)
Study: 28120485
Drug: Buspirone 30
Normalized name: busPIRone 30 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 30 mg
Study: 6130076
Drug: Buspirone 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 40 mg
Study: 7519702
Drug: Buspirone 5
Normalized name: busPIRone 5 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 5 mg
Study: 28120485
Drug: Buspirone 10
Normalized name: busPIRone 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buspirone 10 mg
Study: 10943585
Drug: Thrombolytic agent
Normalized name: Thrombolytic agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thrombolytic agent (urokinase or streptokinase), n = 12
Study: 10943585
Drug: Heparin, n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin, n = 11
Study: 8765432
Drug: UFT plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT plus leucovorin (30 mg/day)
Study: 8765432
Drug: UFT alone
Normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: UFT alone (400 mg/day)
Study: 2013559
Drug: Ketotifen treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketotifen treatment
Study: 6148878
Drug: Nadolol 80
Normalized name: nadolol 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 80 mg/day
Study: 1124717
Drug: Propranolol 160
Normalized name: propranolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol 160 mg/day
Study: 30876431
Drug: Sham tDCS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham tDCS (current stimulation for 30 s) combined with upper limb physical therapy (20 min passive movement + 20 min active mini-bike) for 10 sessions.
Study: 30876431
Drug: Active tDCS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active tDCS (2 mA) combined with upper limb physical therapy.
Study: 20927781
Drug: GDC-0449 (hedgehog
Approvals — FDA: no, EMA: no, PMDA: no
Description: GDC-0449 (hedgehog pathway inhibitor), once per day continuous therapy, oral administration
Study: 9542555
Drug: Propacetamol +
Normalized name: 1,2,3-propanetriol, 2-(4-aminobenzoate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol + PCA morphine
Study: 30648919
Drug: PCV15 Formulation
Normalized name: Hep B, unspecified formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCV15 Formulation A
Study: 26054135
Drug: Acupuncture and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture and moxibustion treatment applied to specific acupuncture points (Shenque, Zhongji, Guanyuan, Qihai, Zigong, Xuebai) for 3 sessions until transfer time.
Study: 23681030
Drug: Intravenous dexamethasone,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dexamethasone, 8 mg
Study: 21685111
Drug: Intranasal DEX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal DEX 1 µg kg(‐1) (Group D)
Study: 19214556
Drug: Beta-alanine supplementation
Normalized name: beta-alanine
DrugBank: beta-Alanine (DB03107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-alanine supplementation (6.4 g day(-1))
Study: 11471851
Drug: Proprietary omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proprietary omeprazole (20 ‐ 40 mg/day depending on age) + metronidazole (30 ‐ 40 mg/kg per day) + amoxycillin (750 mg/day)
Study: 11471851
Drug: Generic omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic omeprazole (20 ‐ 40 mg/day) + metronidazole (30 ‐ 40 mg/kg per day) + amoxycillin (750 mg/day)
Study: 26395410
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment for acetabular deformities
Study: 21676892
Drug: 0.5% ropivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ropivacaine mixed with dexamethasone 8 mg
Study: 21676892
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine mixed with dexamethasone 8 mg
Study: 19706108
Drug: 308-nm excimer
Normalized name: NM-004
DrugBank: NM-004 (DB18066)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 308-nm excimer laser therapy with topical 1% pimecrolimus cream twice daily (group A)
Study: 19706108
Drug: Excimer laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Excimer laser therapy twice per week (group B)
Study: 11306521
Drug: Fluvastatin 40
Normalized name: fluvastatin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin 40 mg/d (n=35)
Study: 7745014
Drug: 75 IU
Normalized name: Follitropin Beta 75 IU/0.5 ML Injection Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 IU human urinary FSH (uFSH) administered subcutaneously (sc)
Study: 31628490
Drug: Romosozumab 210
Normalized name: ROMOSOZUMAB
DrugBank: Romosozumab (DB11866)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Romosozumab 210 mg monthly followed by placebo (n=19)
Study: 25661462
Drug: Dry needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry needling treatment of a single active MTrP
Study: 23382539
Drug: Identically dosed
Normalized name: HUMAN PLACENTA-DERIVED ADHERENT (PDA) CELLS THAT ARE CULTURE-EXPANDED, UNDIFFERENTIATED MESENCHYMAL-LIKE CELLS DERIVED FROM FULL-TERM PLACENTAL TISSUE. CELLULAR IDENTITY: MESENCHYMAL-LIKE STROMAL CELL: CD34-, CD10+, CD105+, AND CD200+.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Identically dosed agents in separate pills taken at different time points during the day
Study: 17879926
Drug: Simplification strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simplification strategy using a boosted protease inhibitor (PI) alone
Study: 10469040
Drug: 180 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 180 mg of oral terfenadine
Study: 10469040
Drug: 120 microg
Normalized name: Betamethasone 120 microgram/mL oral solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 microg of inhaled ipratropium bromide
Study: 30784555
Drug: Prasugrel (3·75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prasugrel (3·75 mg/day)
Study: 9679818
Drug: Thymoglobulin (1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thymoglobulin (1.5 mg/kg/day for 7-14 days)
Study: 9679818
Drug: Atgam (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atgam (15 mg/kg/day for 7-14 days)
Study: 2566160
Drug: Broxaterol (new
Approvals — FDA: no, EMA: no, PMDA: no
Description: Broxaterol (new beta 2-agonist)
Study: 21249218
Drug: Sodium nitrite
Normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium nitrite infusion
Study: 9266780
Drug: Warfarin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin therapy (INR 2.7 +/‐ 1.3)
Study: 9266780
Drug: Low-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity warfarin (INR 1.3 +/‐ 0.08)
Study: 9266780
Drug: Moderate-intensity warfarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-intensity warfarin (INR 2.3 +/‐ 1.1)
Study: 2228932
Drug: Active medication
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active medication groups (Alprazolam and Imipramine combined)
Study: 15355358
Drug: Intense pulsed
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense pulsed light treatment
Study: 26220257
Drug: Foot reflexology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foot reflexology treatment for 20-30 minutes before vaccination
Study: 23730858
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no reflexology treatment)
Study: 24693675
Drug: Proton pump
Normalized name: Proton pump inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton pump inhibitor (Rabeprazole 20 mg once a day)
Study: 24693675
Drug: Histamine H2
Normalized name: Histamine H2 receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine H2 receptor antagonist (Famotidine 20 mg twice a day)
Study: 21205246
Drug: Maximum conservative
Normalized name: Maximum-H
DrugBank: Hydrocortisone (DB00741)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maximum conservative treatment alone
Study: 19663519
Drug: TRC4186 250-2500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC4186 250-2500 mg single dose
Study: 19663519
Drug: TRC4186 500-2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC4186 500-2000 mg multiple doses (twice daily for 6 days)
Study: 19663519
Drug: TRC4186 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC4186 500 mg (fasted) vs 500 mg (fed)
Study: 19663519
Drug: TRC4186 500
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRC4186 500 mg followed by 1000 mg after 7-day washout in elderly subjects
Study: 9429043
Drug: 0.05 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg.kg‐1 rocuronium, 3 min before 2 mg.kg‐1 succinylcholine (ROC‐3 min)
Study: 9429043
Drug: 0.05 mg.kg‐1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg.kg‐1 rocuronium, 1.5 min before 2 mg.kg‐1 succinylcholine (ROC‐1.5 min)
Study: 23080351
Drug: Liposome bupivacaine
Normalized name: bupivacaine liposome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liposome bupivacaine 266 mg
Study: 11738299
Drug: Aspirin (ASA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (ASA) users
Study: 9033324
Drug: Heparin loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin loading dose of 300 U/kg followed by 3 U/mL of heparin in the prime (high-dose group)
Study: 8285609
Drug: Rufloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufloxacin 400 mg on day 1 and 200 mg daily for 9 days (n = 64)
Study: 8285609
Drug: Rufloxacin 300
Normalized name: ofloxacin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rufloxacin 300 mg on day 1 and 150 mg daily for 9 days (n = 63)
Study: 8285609
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg three times a day for 10 days (n = 65)
Study: 17254453
Drug: IVIG 1
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 1 g/kg
Study: 17254453
Drug: IVIG 2
Normalized name: Intravenous immunoglobulin (IVIg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIG 2 g/kg
Study: 9625835
Drug: Serum p53
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum p53 antibodies positive patients (33 out of 57)
Study: 8003109
Drug: Glucose and
Normalized name: Glucose and treacle only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose and xylitol mixture (1:1; 2 mg/kg BW/min)
Study: 8003109
Drug: Glucose-containing electrolyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-containing electrolyte solution (0.8 mg/kg BW/min)
Study: 8003109
Drug: Glucose-xylitol mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose-xylitol mixture (4 mg/kg BW/min)
Study: 18544005
Drug: Tetrabenazine treatment
Normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrabenazine treatment for 2 years
Study: 18544005
Drug: Tetrabenazine treatment
Normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tetrabenazine treatment for a mean duration of 19 months
Study: 1725540
Drug: nifedipine 10
Normalized name: nifedipine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 10 mg t.i.d.
Study: 1725540
Drug: nifedipine 20
Normalized name: nifedipine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: nifedipine 20 mg t.i.d.
Study: 1725540
Drug: diltiazem 60
Normalized name: DILTIAZEM 60MG 12HR CAP,SA
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem 60 mg t.i.d.
Study: 1725540
Drug: diltiazem 120
Normalized name: diltiazem 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: diltiazem 120 mg t.i.d.
Study: 1725540
Drug: verapamil 40
Normalized name: verapamil 40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: verapamil 40 mg q.i.d.
Study: 6596060
Drug: Intracoronary streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary streptokinase therapy
Study: 10497668
Drug: Minolest (16.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minolest (16.5 g/day)
Study: 7590572
Drug: Effervescent tablet
Normalized name: Pain Relief Effervescent Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Effervescent tablet of sucralfate (2.0 g twice daily)
Study: 7590572
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (effervescent and granular)
Study: 20215608
Drug: Hepatitis A
Normalized name: HEPATITIS A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatitis A vaccine (control)
Study: 10367588
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of partial agonists with ICI 118,551
Study: 3896659
Drug: Slow-release indomethacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release indomethacin (50 mg)
Study: 6510016
Drug: Diflunisal (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal (250 mg)
Study: 17584562
Drug: Nebivolol 10
Normalized name: nebivolol 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol 10 mg
Study: 25139609
Drug: Subcutaneous continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous continuous glucose monitoring (CGM)
Study: 22021700
Drug: Citalopram (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (2 ml intravenously)
Study: 22021700
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 ml of 0.9% NaCl intravenously)
Study: 19692881
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (100 mL 0.9% NaCl infused intravenously)
Study: 11103054
Drug: Epoetin alfa
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epoetin alfa high-dose (40,000 U)
Study: 9263613
Drug: Ipriflavone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ipriflavone (200 mg T.I.D. at meals) plus 1 g oral calcium daily
Study: 9263613
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 1 g oral calcium daily
Study: 8518909
Drug: Division of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Division of the superior rectal artery
Study: 24525635
Drug: Baclofen (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baclofen (40 mg/d) + Citalopram (20 to 60 mg/d)